

# Willemijn M Meijer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/752078/publications.pdf>

Version: 2024-02-01

16  
papers

393  
citations

933447

10  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

581  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vasopressin Differentially Affects Handgrip Force of Expectant Fathers in Reaction to Own and Unknown Infant Faces. <i>Frontiers in Behavioral Neuroscience</i> , 2019, 13, 105.	2.0	16
2	Effects of vasopressin on neural processing of infant crying in expectant fathers. <i>Hormones and Behavior</i> , 2018, 103, 19-27.	2.1	26
3	Nature and management of duplicate medication alerts. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 831-837.	4.4	6
4	Association between ADHD drug use and injuries among children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 95-102.	4.7	35
5	Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder in Children: Incidence, Prevalence, and Treatment Patterns in The Netherlands. <i>Clinical Therapeutics</i> , 2011, 33, 188-203.	2.5	73
6	Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 972-978.	1.9	6
7	Pharmacists' role in improving awareness about folic acid: a pilot study on the process of introducing an intervention in pharmacy practice. <i>International Journal of Pharmacy Practice</i> , 2010, 12, 29-35.	0.6	16
8	Improved periconceptional use of folic acid after patient education in pharmacies: promising results of a pilot study in the Netherlands. <i>International Journal of Pharmacy Practice</i> , 2010, 13, 47-51.	0.6	15
9	Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. <i>Current Medical Research and Opinion</i> , 2010, 26, 2565-2574.	1.9	5
10	Current issues around the pharmacotherapy of ADHD in children and adults. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 509-516.	1.4	35
11	Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. <i>Current Medical Research and Opinion</i> , 2008, 24, 3217-3222.	1.9	20
12	The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 675-682.	1.9	8
13	Clomiphene and hypospadias on a detailed level: Signal or chance?. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2006, 76, 249-252.	1.6	31
14	Can folic acid protect against congenital heart defects in down syndrome?. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2006, 76, 714-717.	1.6	10
15	Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. <i>Reproductive Toxicology</i> , 2005, 20, 203-207.	2.9	33
16	Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2004, 114, 182-188.	1.1	58